Table 1 Patient baseline characteristics
Characteristics | Before PSM | P value | After PSM | P value | ||
|---|---|---|---|---|---|---|
No-bolus (N = 275) No. of patients (%) | Bolus (N = 254) No. of patients (%) | No-bolus (N = 175) No. of patients (%) | Bolus (N = 175) No. of patients (%) | |||
Age, median (range) | 54 (33–83) | 55 (32–82) | 0.991 | 53 (31–79) | 54 (33–78) | 0.841 |
(y) pT stage | 0.230 | 0.429 | ||||
0–2 | 264 (96.00%) | 238 (93.70%) | 169 (96.57%) | 166 (94.86%) | ||
3–4 | 11 (4.00%) | 16 (6.30%) | 6 (3.43%) | 9 (5.14%) | ||
(y) pN stage | 0.121 | 0.587 | ||||
0–1 | 155 (56.36%) | 160 (62.99%) | 105 (60.00%) | 100 (57.14%) | ||
2–3 | 120 (43.64%) | 94 (37.01%) | 70 (40.00%) | 75 (42.86%) | ||
Subtype | 0.007* | 0.062 | ||||
Luminal A | 44 (16.00%) | 47 (18.50%) | 21 (12.00%) | 37 (21.14%) | ||
Luminal B | 171 (62.20%) | 124 (48.80%) | 111 (63.43%) | 92 (52.57%) | ||
Triple negative | 32 (11.60%) | 44 (17.30%) | 27 (13.43%) | 24 (13.71%) | ||
Her-2 positive | 24 (8.70%) | 38 (15.00%) | 16 (11.14%) | 22 (12.58%) | ||
Unknown | 4 (1.50%) | 1 (0.40%) | ||||
Grade | 0.914 | 0.912 | ||||
1–2 | 162 (58.90%) | 150 (59.05%) | 108 (61.71%) | 109 (62.28%) | ||
3 | 91 (33.10%) | 86 (33.86%) | 67 (38.29%) | 66 (37.72%) | ||
Unknown | 22 (8.00%) | 18 (7.09%) | ||||
Hormone therapy | 0.200 | 0.560 | ||||
Yes | 193 (70.18%) | 165 (64.96%) | 120 (68.57%) | 125 (71.43%) | ||
No | 82 (29.82%) | 89 (35.04%) | 55 (31.43%) | 50 (28.57%) | ||
Peri operational chemotherapy | 0.001* | 0.722 | ||||
Adjuvant | 197 (71.64%) | 144 (56.69%) | 127 (72.57%) | 124 (70.86%) | ||
Neoadjuvant | 66 (24.00%) | 100 (39.37%) | 48 (27.43%) | 51 (29.14%) | ||
No chemotherapy | 12 (4.36%) | 10 (3.94%) | 0 (0.00%) | 0 (0.00%) | ||
Anti-Her2 therapy | 0.150 | 0.726 | ||||
No | 208 (75.60%) | 178 (70.10%) | 121 (69.14%) | 124 (70.86%) | ||
Yes | 67 (24.40%) | 76 (29.90%) | 54 (30.86%) | 51 (29.14%) | ||
Margin | 0.788 | 0.792 | ||||
Negative | 253 (50.50%) | 226 (45.10%) | 168 (96.00%) | 167 (95.43%) | ||
Positive | 9 (1.80%) | 11 (2.20%) | 7 (4.00%) | 8 (4.57%) | ||
Close | 1 (0.20%) | 1 (0.20%) | ||||
LVI | 0.127 | 0.693 | ||||
Positive | 122 (44.36%) | 93 (36.61%) | 65 (37.14%) | 72 (41.14%) | ||
Negative | 83 (30.18%) | 79 (31.10%) | 58 (33.14%) | 57 (32.57%) | ||
Unknown | 70(25.46%) | 82(32.29%) | 52(29.72%) | 46(26.29%) | ||